CMG Pharmaceutical Co., Ltd.

KOSDAQ:A058820 Stock Report

Market Cap: ₩239.2b

CMG Pharmaceutical Balance Sheet Health

Financial Health criteria checks 3/6

CMG Pharmaceutical has a total shareholder equity of ₩196.0B and total debt of ₩76.1B, which brings its debt-to-equity ratio to 38.8%. Its total assets and total liabilities are ₩304.7B and ₩108.7B respectively.

Key information

38.8%

Debt to equity ratio

₩76.12b

Debt

Interest coverage ration/a
Cash₩82.84b
Equity₩196.03b
Total liabilities₩108.69b
Total assets₩304.72b

Recent financial health updates

No updates

Recent updates

There May Be Reason For Hope In CMG Pharmaceutical's (KOSDAQ:058820) Disappointing Earnings

Nov 20
There May Be Reason For Hope In CMG Pharmaceutical's (KOSDAQ:058820) Disappointing Earnings

CMG Pharmaceutical's (KOSDAQ:058820) Solid Earnings Are Supported By Other Strong Factors

Mar 27
CMG Pharmaceutical's (KOSDAQ:058820) Solid Earnings Are Supported By Other Strong Factors

Did You Participate In Any Of CMG Pharmaceutical's (KOSDAQ:058820) Fantastic 203% Return ?

Dec 28
Did You Participate In Any Of CMG Pharmaceutical's (KOSDAQ:058820) Fantastic 203% Return ?

Financial Position Analysis

Short Term Liabilities: A058820's short term assets (₩133.2B) exceed its short term liabilities (₩83.3B).

Long Term Liabilities: A058820's short term assets (₩133.2B) exceed its long term liabilities (₩25.4B).


Debt to Equity History and Analysis

Debt Level: A058820 has more cash than its total debt.

Reducing Debt: A058820's debt to equity ratio has increased from 0% to 38.8% over the past 5 years.

Debt Coverage: A058820's debt is not well covered by operating cash flow (10.3%).

Interest Coverage: Insufficient data to determine if A058820's interest payments on its debt are well covered by EBIT.


Balance Sheet


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/28 21:27
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

CMG Pharmaceutical Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution